APA Alıntı

Del Re, M., Rofi, E., Cappelli, C., Puppo, G., Crucitta, S., Valeggi, S., . . . Petrini, I. (2019). The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: A case report. BMC Cancer.

Chicago Stili Alıntı

Del Re, Marzia, Eleonora Rofi, Carla Cappelli, Gianfranco Puppo, Stefania Crucitta, Simona Valeggi, Antonio Chella, Romano Danesi, ve Iacopo Petrini. "The Increase in Activating EGFR Mutation in Plasma Is an Early Biomarker to Monitor Response to Osimertinib: A Case Report." BMC Cancer 2019.

MLA Alıntı

Del Re, Marzia, et al. "The Increase in Activating EGFR Mutation in Plasma Is an Early Biomarker to Monitor Response to Osimertinib: A Case Report." BMC Cancer 2019.